Recent Advances in Understanding of Preeclampsia

Bdolah, Yuval; Karumanchi, S. Ananth; Sachs, Benjamin P.
October 2005
Croatian Medical Journal;2005, Vol. 46 Issue 5, p728
Academic Journal
Despite intensive research, preeclampsia still accounts for significant morbidity and mortality for the mother and the neonate, especially in developing countries. Recent studies have suggested that excess secretion of a naturally occurring anti-angiogenic molecule of placental origin referred to as soluble fms-like tyrosine kinase-1 (sFlt-1, also referred to as sVEGFR-1) may contribute to the pathogenesis of preeclampsia. sFlt-1 acts by antagonizing two pro-angiogenic molecules -- vascular endothelial growth factor (VEGF) and placental growth factor (PlGF). Abnormalities in the angiogenic balance have been proposed as having a major role in themolecular cascade leading to proteinuria, hypertension, and endothelial dysfunction. Further evidence supports the hypothesis that angiogenic balance is crucial to differentiation and invasion of cytotrophoblasts. The abnormal placentation and the accompanying hypoxia may, in turn, result in more sFlt-1 production, thus leading to a vicious cycle of sFlt-1 production, eventually causing preeclampsia. These recent discoveries may facilitate the development of novel strategies for the diagnosis and therapy of preeclampsia.


Related Articles

  • Effect of Antihypertensive Therapy with Alpha Methyldopa on Levels of Angiogenic Factors in Pregnancies with Hypertensive Disorders. Khalil, Asma; Muttukrishna, Shanthi; Harrington, Kevin; Jauniaux, Eric // PLoS ONE;2008, Vol. 3 Issue 7, p1 

    Background: Antihypertensive drugs are believed to lower blood pressure in pre-eclampsia by direct or central vasodilatory mechanisms. However, they could also act by decreasing production of anti-angiogenic proteins involved in the pathophysiology of hypertension and proteinuria in...

  • Low urinary placental growth factor is a marker of pre-eclampsia. Aggarwal, P. K.; Jain, V.; Sakhuja, V.; Karumanchi, S. A.; Jha, V. // Kidney International;Feb2006, Vol. 69 Issue 3, p621 

    Recent reports of increased serum levels of soluble fms-like tyrosine kinase 1 (sFlt-1) and decreased levels of placental growth factor (PlGF) suggest the key role of angiogenic factors in development of pre-eclampsia. PlGF is excreted in urine, and reduced urinary level has been suggested as a...

  • Difference of concentration of placental soluble fms-like tyrosine kinase-1(sFlt-1), placental growth factor (PlGF), and sFlt-1/ PlGF ratio in severe preeclampsia and normal pregnancy. Gurnadi, Jeffry Iman; Mose, Johannes; Handono, Budi; Satari, Mieke H.; Anwar, Anita Deborah; Fauziah, Prima Nanda; Yogi Pramatirta, A.; Davidson Rihibiha, Dwi // BMC Research Notes;10/5/2015, Vol. 8 Issue 1, p1 

    Background: Placental soluble fms-like tyrosine kinase-1 (sFlt-1) which is an antagonist of vascular endothelial growth factor and placental growth factor (PIGF), is considered as one of etiology factors cause endothelial damage in preeclampsia due to increase of sFlt-1 level that change...

  • Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. Shibuya, Masabumi // Journal of Biochemistry;Jan2013, Vol. 153 Issue 1, p13 

    Vascular endothelial growth factors (VEGFs) belong to the platelet-derived growth factor supergene family, and they play central roles in the regulation of angiogenesis and lymphangiogenesis. VEGF-A, the major factor for angiogenesis, binds to two tyrosine kinase (TK) receptors, VEGFR-1 (Flt-1)...

  • Soluble FLT1 sensitizes endothelial cells to inflammatory cytokines by antagonizing VEGF receptor-mediated signalling. Cindrova-Davies, Tereza; Sanders, Deborah A.; Burton, Graham J.; Charnock-Jones, D. Stephen // Cardiovascular Research;Feb2011, Vol. 89 Issue 3, p671 

    Aims Pre-eclampsia affects 5–7% of pregnancies, and is a major cause of maternal and foetal death. Elevated serum levels of placentally derived splice variants of the vascular endothelial growth factor (VEGF) receptor, soluble fms-like tyrosine kinase-1 (sFLT1), are strongly implicated in...

  • Soluble fms-like tyrosine kinase-1 and atherosclerosis in chronic kidney disease. Luft, Friedrich C // Kidney International;Feb2014, Vol. 85 Issue 2, p238 

    Vascular endothelial growth factor (VEGF) and its cousins, such as placental growth factor, have moved into the daily clinical arena. One-step-removed regulators, such as the VEGF splice variant soluble fms-like tyrosine kinase-1 (sFlt-1), now clinically emerge. sFlt-1 keeps our corneas 'clean.'...

  • First trimester serum angiogenic/anti-angiogenic status in twin pregnancies: relationship with assisted reproduction technology. Sánchez, O; Llurba, E.; Marsal, G.; Domínguez, C.; Aulesa, C.; Sánchez-Durán, M.A.; Goya, M.M.; Alijotas-Reig, J.; Carreras, E.; Cabero, L. // Human Reproduction;Feb2012, Vol. 27 Issue 2, p358 

    BACKGROUND The risk of pre-eclampsia (PE) increases in twin pregnancies, especially when assisted reproduction technologies (ART) are used. The aim of this study was to assess angiogenic/anti-angiogenic factors in maternal serum in the first trimester of twin pregnancies and establish if the...

  • Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Guillaume Bollée; Natacha Patey; Géraldine Cazajous; Caroline Robert; Jean-Michel Goujon; Fadi Fakhouri; Patrick Bruneval; Laure-Hélène Noël; Bertrand Knebelmann // Nephrology Dialysis Transplantation;Feb2009, Vol. 24 Issue 2, p682 

    Background. Drugs targeting the VEGF pathway are associated with renal adverse events, including proteinuria, hypertension and thrombotic microangiopathy (TMA). Most cases of TMA are reported secondary to bevacizumab. It was shown recently that sunitinib, a small molecule inhibiting several...

  • Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy. Izzedine, Hassan; Mangier, Melanie; Ory, Virginie; Zhang, Shao-Yu; Sendeyo, Kelhia; Bouachi, Khedidja; Audard, Vincent; Péchoux, Christine; Soria, Jean C; Massard, Christophe; Bahleda, Rastilav; Bourry, Edward; Khayat, David; Baumelou, Alain; Lang, Philippe; Ollero, Mario; Pawlak, Andre; Sahali, Djillali // Kidney International;Feb2014, Vol. 85 Issue 2, p457 

    Renal toxicity constitutes a dose-limiting side effect of anticancer therapies targeting vascular endothelial growth factor (VEGF). In order to study this further, we followed up 29 patients receiving this treatment, who experienced proteinuria, hypertension, and/or renal insufficiency. Eight...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics